Lanreotide Sun (Lanreotide)

Lanreotide mimics natural somatostatin and binds primarily to somatostatin receptors 2 and 5 on endocrine and neuroendocrine cells. This binding blocks intracellular signaling pathways that trigger the release of growth hormone, insulin, glucagon, serotonin and other peptides, thereby reducing pathological hormone secretion.

The exact dose and dosing interval are individualized by the prescribing clinician based on the patient’s disease severity, hormone levels, response to therapy, and tolerability. Lanreotide is supplied as a pre‑filled injectable formulation, and the prescriber decides the appropriate regimen.

Safety data for Lanreotide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lanreotide Sun, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Both lanreotide and octreotide are long‑acting somatostatin analogs that target the same receptors. Lanreotide is typically administered as a deep‑subcutaneous injection every 4–8 weeks, whereas octreotide may be given monthly or as a long‑acting repeat‑dose formulation. Clinical efficacy is comparable, but dosing frequency and formulation preferences differ between patients and clinicians.

Lanreotide Sun should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods.

The medication is supplied as a sterile, pre‑filled syringe for deep subcutaneous injection. A healthcare professional administers the dose into the fatty tissue of the abdomen, thigh or upper arm, typically every four to eight weeks, depending on the prescribed schedule.

Serious adverse events include gallbladder disease such as cholelithiasis, pancreatitis, and severe hypersensitivity reactions like anaphylaxis or angioedema. Patients should be monitored for abdominal pain, jaundice, or signs of allergic reaction, and appropriate medical attention should be sought promptly.

Lanreotide is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with active gallbladder disease, severe uncontrolled diabetes, or those who have experienced pancreatitis, as the drug may exacerbate these conditions.